Healthcare

Ceretas (ASX:CTS) is an emerging medical device company developing a non-invasive ultrasound platform designed to address neurological conditions, including behavioural and psychological symptoms associated with Alzheimer's disease.

Clinical-stage biotechnology companies often focus on one asset and one indication, but Entropy Neurodynamics (ASX:ENP) is taking a broader approach by evaluating its lead therapy across multiple conditions through a single clinical programme.

Epiminder (ASX:EPI) entered the ASX market with a different challenge from many early-stage medical device companies. Rather than seeking initial regulatory clearance, the company is focused on commercial execution following FDA authorisation for its Minder implantable epilepsy monitoring system.

Clinical-stage biotechnology companies are often driven by development milestones rather than traditional earnings, and Prescient Therapeutics (ASX:PTX) is approaching an important point in the development of its lead oncology candidate.

The transition from preclinical development to patient dosing represents an important milestone for biotechnology companies, and Arovella Therapeutics (ASX:ALA) is approaching that stage with its lead cell therapy programme.

SomnoMed (ASX:SOM), the Sydney-based developer of oral devices for obstructive sleep apnoea, closed FY26 with higher revenue, improvedEarningsmargins and a relatively low level of debt.

The approval expands Telix Pharmaceuticals’ (ASX:TLX) Precision Medicine portfolio and follows the regulatory review of the company’s New Drug Application for the product.